Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study to Evaluate the Pharmacokinetics and Safety of IBI362 Lyophilized Powder and IBI362 Liquid Formulation in Healthy Chinese Male Subjects

NCT04773977 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.

NCT NCT04773977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04773977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study to Evaluate the Pharmacokinetics and Safety of IBI362 Lyophilized Powder and IBI362 Liquid Formulation in Healthy Chinese Male Subjects
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 3, 2021
Completion date
June 17, 2021
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight/obesity